Funded Startups in Carlsbad
Carlsbad’s disclosed rounds show a steep size gap: Airspace’s $70M (2022-05-25) is the largest disclosed amount, materially higher than the next-largest di…
Carlsbad’s disclosed rounds show a steep size gap: Airspace’s $70M (2022-05-25) is the largest disclosed amount, materially higher than the next-largest disclosed rounds clustered around $60M–$53M (Allez Health $60M on 2024-05-22; ViaSat $53M on 2022-04-21 and Carlsmed $53M on 2024-03-18). The most recent entry, ALZpath at $8M on 2026-07-21, sits far below that top tier, while the smallest disclosed round is Oral Genome at $50K on 2026-06-24.
Timing and sector/stage mix also cluster. Among the displayed entries, the disclosed dates span 2020-12-07 to 2026-07-21, and 41 of 49 rows have disclosed amounts (8 are undisclosed). Biotechnology appears frequently (e.g., ALZpath 2026-07-21 $8M; Palisade Bio 2026-01-07 $500K; Allez Health 2024-05-22 $60M; Macro Biologics 2025-12-16 $5M), while “Series Unknown” is a dominant labeling pattern across entries such as ALZpath (2026-07-21 $8M) and Proper Voltage (2026-05-26 $7M).
Most recent rounds
49 shownRelated listings
Frequently asked
What’s the largest disclosed round for Carlsbad in this list, and how much does it stand out?
Airspace is the largest disclosed amount at $70M (2022-05-25). The next-largest disclosed rounds sit in a narrower band around $60M–$53M, including Allez Health $60M (2024-05-22) and both ViaSat and Carlsmed at $53M (2022-04-21 and 2024-03-18, respectively).
Are there clear outliers in funding size, or is most capital concentrated around a single range?
Yes: after the $70M top round, the list’s disclosed amounts generally cluster below $50M, with the smallest disclosed round at $50K for Oral Genome (2026-06-24). The $60M and $53M entries (Allez Health 2024-05-22; ViaSat 2022-04-21; Carlsmed 2024-03-18) form a mid-to-upper tier that sharply contrasts with smaller disclosed rounds like LenderSquared’s $340K (2025-10-17).
How much of the most recent activity is within a tight window (e.g., last 90 days shown)?
Using the latest displayed date of 2026-07-21, several rounds fall in the prior ~90 days, including ALZpath $8M (2026-07-21), Oral Genome $50K (2026-06-24), and Rapalogix Health $20M and ALT Sports Data $5M (both in late June 2026—2026-06-23). There’s also a recent concentration of disclosed health/biotech entries such as ImpediMed $11M (2026-05-04) and Ceresti Health $10M (2026-05-11).
Does any stage labeling dominate, and how does that affect analysis of deal size?
“Series Unknown” appears frequently across disclosed entries, including ALZpath ($8M on 2026-07-21), Proper Voltage ($7M on 2026-05-26), and ImpediMed ($11M on 2026-05-04). This means sizing comparisons by stage are constrained: the dataset also shows multiple explicit stages (e.g., Rapalogix Health Series A $20M on 2026-06-23; GigaIO Series B $21M on 2025-07-17; Airspace Series D $70M on 2022-05-25).
Which sectors cluster most consistently in this Carlsbad funding snapshot?
Biotechnology repeats across many entries—ALZpath ($8M on 2026-07-21), Rapalogix Health ($20M on 2026-06-23), Palisade Bio ($500K on 2026-01-07), and Allez Health ($60M on 2024-05-22) are examples—suggesting biotech is a core theme in the disclosed rounds. Health Care is also common (e.g., Nalu Medical $50M on 2025-09-15; SeaSpine $30M on 2022-07-19; Carlsmed $53M on 2024-03-18), often pairing large dollar amounts with medical/biotech labels.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.